Get Free Delivery With No Minimum Order

ESOPOLE 20/MG CAP 28/CAP
- Sku : I-032069
Key features
ESOPOLE 20 mg is a modified-release capsule containing the active ingredient esomeprazole 20 mg. It reduces gastric acid secretion by inhibiting the H+/K+-ATPase (proton pump) in gastric parietal cells, providing sustained acid suppression. ESOPOLE is indicated for symptomatic gastro-oesophageal reflux disease and for healing and maintenance of healed erosive esophagitis; pathological hypersecretory conditions including Zollinger-Ellison syndrome; as part of combination therapy for H. pylori eradication to reduce duodenal ulcer recurrence; and to reduce the risk of NSAID‑associated gastric ulcers in at‑risk patients. Available as prescription-only modified-release capsules in a pack of 28.- Brand: ESOPOLE
- Active Ingredient: ESOMEPRAZOLE 20mg
- Strength: 20mg
- Dosage Form: Modified-release capsule
- Pack Size: 28 Capsules
- Route: Oral use
- Prescription Status: Prescription
- Therapeutic Class: Gastrointestinal
- Pharmacological Group: Proton Pump Inhibitors
- Drug Class: Proton Pump Inhibitor (PPI), Benzimidazole derivative
- Manufacturer: Hetero Labs Limited Unit - III
- Country of Origin: India
- SFDA Registration No.: 24-5362-21
- Shelf Life: 24 months
- Storage: store below 30°c
- Gi Condition: Acid Reflux/GERD
Indications
Approved Uses
GERD (symptomatic reflux) and erosive esophagitis (healing and maintenance of healed erosive esophagitis); pathological hypersecretory conditions including Zollinger-Ellison syndrome; H. pylori eradication as part of combination therapy to reduce duodenal ulcer recurrence; risk reduction/prevention of NSAID‑associated gastric ulcer in at‑risk patients.
Off-Label Uses
Common off-label uses include laryngopharyngeal reflux (LPR), stress ulcer prophylaxis in critically ill patients (institution/protocol dependent), and as part of therapy for eosinophilic esophagitis (PPI-responsive EoE).
Side Effects
Common Side Effects
Headache, nausea, diarrhea, abdominal pain, flatulence, constipation, dry mouth, dizziness
Side Effect Frequency
Common (1-10%): headache, abdominal pain, diarrhea, nausea/vomiting, flatulence, constipation. Uncommon (0.1-1%): dizziness, dry mouth, dermatitis, pruritus, urticaria. Rare/very rare (<0.1%): hypersensitivity reactions, interstitial nephritis, severe cutaneous adverse reactions (e.g., SJS/TEN), hepatitis/liver enzyme elevations; hypomagnesemia is typically reported as rare and usually with long-term use.
Safety & Warnings
Driving Warning
Safe
Drug Interactions
Drug Interactions
Key interactions include: clopidogrel (reduced activation/antiplatelet effect), warfarin (↑INR/bleeding risk), high-dose methotrexate (↑levels/toxicity), digoxin (↑absorption), drugs needing acidic pH (e.g., ketoconazole/itraconazole, iron salts) (↓absorption), antiretrovirals (contraindicated with nelfinavir and rilpivirine; avoid/monitor with atazanavir), tacrolimus (↑levels), CYP inducers (rifampin, St. John’s wort) (↓esomeprazole exposure), and CYP2C19 substrates such as diazepam/citalopram (↑exposure in some patients).
Alcohol Interaction
Safe
Special Populations
Breastfeeding
Caution
Elderly
Standard adult dosing; no routine dose adjustment required
Kidney Impairment
No adjustment needed.
Liver Impairment
Mild-to-moderate impairment: no adjustment needed. Severe impairment (Child-Pugh Class C): do not exceed 20 mg/day.
Storage & Patient Advice
Missed Dose
Take the missed dose as soon as remembered unless it is close to the next scheduled dose; if close, skip the missed dose and resume the regular schedule. Do not double doses.
Overdose
Symptoms are usually non-specific (e.g., confusion, drowsiness, blurred vision, tachycardia, nausea/vomiting, headache); management is supportive/symptomatic, and hemodialysis is unlikely to be useful.
Pharmacology
Half-Life
Approximately 1-1.5 hours (plasma elimination half-life) after oral dosing
Bioavailability
Systemic exposure comparable to enteric-coated formulation; bioavailability data not specified for 20 mg modified-release
Metabolism
Hepatic metabolism primarily via CYP2C19 and secondarily via CYP3A4
Product Information
Available Dosage Forms
Modified-release capsule, delayed-release tablet, powder for oral suspension, intravenous injection
Generic Availability
Yes
Gi Condition
Acid Reflux/GERD
Legal Disclaimer - Al Mujtama Pharmacy
The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.
Al Mujtama Pharmacy assumes no legal or medical liability for:
- Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
- Any discrepancy between the information provided and the product's package insert or SFDA guidelines
- Any misuse of medication resulting from personal interpretation of the content displayed
Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.
By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.
Your health is a trust - always consult your doctor first.
-1744229570.gif)



